A related question.
Having found no dose-limiting toxicity with Cu67 attached to one targeting agent, can Clarity skip the dose escalatoon stage in therapeutic trials with Cu67 attached to different targeting agents?
Research/Valuation, page-205
-
- There are more pages in this discussion • 335 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.44 |
Change
0.300(4.89%) |
Mkt cap ! $2.025B | |||
| Open | High | Low | Value | Volume |
| $6.20 | $6.50 | $6.19 | $12.16M | 1.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 455 | $6.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.44 | 1726 | 13 |
View Market Depth
| Last trade - 15.34pm 23/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |